Keywords: Proximagen, GlaxoSmithKline, CNS drug development, Cognition disorders

Proximagen acquires two CNS drug development programs from GlaxoSmithKline

Article | 23 December 2010

Print This

The UK’s Proximagen Group (AIM: PRX), whose principal focus on the treatment of disorders of the central nervous ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in